SOPHiA GENETICS (NASDAQ:SOPH) Stock: Insider Manuela Valente Sells 4,240 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Manuela Valente sold 4,240 shares of SOPHiA GENETICS stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $8.13, for a total value of $34,471.20. Following the transaction, the insider owned 206,210 shares in the company, valued at $1,676,487.30. This trade represents a 2.01% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

SOPHiA GENETICS Price Performance

Shares of SOPH opened at $7.30 on Friday. The stock has a 50 day simple moving average of $7.88 and a 200 day simple moving average of $6.15. SOPHiA GENETICS SA has a 52-week low of $3.75 and a 52-week high of $8.98. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. The firm has a market capitalization of $612.40 million, a PE ratio of -6.35 and a beta of 0.95.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its earnings results on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%.The company had revenue of $23.31 million for the quarter, compared to analyst estimates of $21.72 million. Sell-side analysts predict that SOPHiA GENETICS SA will post -0.77 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Silverberg Bernstein Capital Management LLC boosted its stake in shares of SOPHiA GENETICS by 8.7% during the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock worth $257,000 after buying an additional 4,155 shares during the last quarter. Principal Financial Group Inc. increased its position in shares of SOPHiA GENETICS by 0.7% in the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after acquiring an additional 9,800 shares during the last quarter. First Dallas Securities Inc. bought a new stake in SOPHiA GENETICS during the first quarter worth about $50,000. 1492 Capital Management LLC raised its holdings in SOPHiA GENETICS by 8.4% during the first quarter. 1492 Capital Management LLC now owns 225,751 shares of the company’s stock worth $1,117,000 after acquiring an additional 17,406 shares in the last quarter. Finally, Royal Bank of Canada boosted its position in SOPHiA GENETICS by 3,130.2% during the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock valued at $96,000 after purchasing an additional 18,781 shares during the last quarter. Institutional investors own 31.59% of the company’s stock.

SOPHiA GENETICS News Summary

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Myriad Genetics and SOPHiA GENETICS are partnering with AstraZeneca to use prostate cancer technology involving genomic-instability scoring. The agreement provides potential commercial and validation benefits for SOPH by connecting its analytics capabilities with Myriad’s testing expertise and AstraZeneca’s oncology development programs. Myriad, SOPHiA partner with AstraZeneca to use prostate cancer technology
• Positive Sentiment: The collaboration reinforces SOPHiA GENETICS’ positioning in cancer genomics and could increase adoption of its cloud-based SOPHiA DDM platform. However, the reports do not disclose financial terms, revenue guidance or a specific near-term contribution, so the immediate earnings impact remains uncertain. SOPHiA GENETICS Partners Myriad Genetics To Advance Prostate Genomic Instability Score Technology
• Neutral Sentiment: Several executives and directors, including the CEO, chairman, CFO and CTO, sold shares at approximately $8.04–$8.13. The sales were made under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, and each insider retained a substantial position. SOPHiA GENETICS insider trading report
• Negative Sentiment: The broad group of insider sales totaled roughly $669,000 and may create some near-term selling pressure or investor caution, despite the transactions appearing administrative rather than discretionary bearish bets.

Wall Street Analysts Forecast Growth

Several research firms recently commented on SOPH. HC Wainwright boosted their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Zacks Research raised SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. Finally, BTIG Research increased their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, SOPHiA GENETICS has a consensus rating of “Hold” and a consensus price target of $10.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.